Author

K. Koshizuka

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:perturbation response prediction· 2 Research Focus:cell signaling & trafficking· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

J. S. Gutkind· 2 shared Z. Wang· 2 shared A. Dayoub· 1 shared A. E. Smith· 1 shared A. Gasco Hernandez· 1 shared A. Ho· 1 shared A. Kishore· 1 shared A. McCloskey· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. S. Gutkind

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC

Y. Goto, K. Koshizuka, T. Ando, H. Izumi, X. Wu, K. Ford, X. Feng, Z. Wang, N. Arang, M. M. Allevato, A. Kishore, P. Mali, J. S. Gutkind

This study identifies mTOR inhibition as a way to prevent adaptive resistance to CDK4/6 blockade in HNSCC by targeting cell cycle pathways.

bioRxiv · Aug 7, 2023Cancer Biology

Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity

A. E. Smith, S. Chan, Z. Wang, A. McCloskey, Q. Reilly, J. Z. Wang, H. V. Patel, K. Koshizuka, H. S. Soifer, L. Kessler, A. Dayoub, V. Villaflor, D. Adkins, J. Y. Bruce, A. Ho, , S. Malik

This study combines tipifarnib and alpelisib to target PI3K-mTOR and HRAS in HNSCC, showing synergy in mTOR inhibition and clinical potential for R/M HNSCC patients.

bioRxiv · Jan 17, 2023 · PreprintCancer Biology